

Online Resource 2: Clinical vertebral and non-vertebral fractures during teriparatide treatment (0 to 24 months) for the active treatment cohort

Time interval (months)	N ^a	Number of fractures per 10,000 patient years	Total number of fractures	Patients with ≥1 fracture, <i>n</i> (%) ^b	Odds of fracture (95% CI) ^c	Odds ratio ^{c,d} (95% CI)	<i>p</i> value ^d
<i>Clinical vertebral fractures</i>							
0 to 6	1454	237	17	16 (1.1)	0.006 (0.002–0.017)	-	-
>6 to 12	1384	45	3	2 (0.1)	0.001 (0.000–0.004)	0.13 (0.03–0.57)	0.007
>12 to 18	1295	48	3	3 (0.2)	0.001 (0.000–0.005)	0.21 (0.06–0.72)	0.013
>18 to 24	1087	73	3	3 (0.3)	0.001 (0.000–0.006)	0.25 (0.07–0.87)	0.029
Total ^e	1454		26	24 (1.7)			
<i>Non-vertebral fractures</i>							
0 to 6	1454	433	31	29 (2.0)	0.010 (0.005–0.021)	-	-
>6 to 12	1384	416	28	26 (1.9)	0.009 (0.004–0.020)	0.94 (0.56–1.56)	0.800
>12 to 18	1295	353	22	20 (1.5)	0.008 (0.003–0.018)	0.77 (0.44–1.34)	0.348
>18 to 24	1087	363	15	14 (1.3)	0.006 (0.003–0.016)	0.64 (0.33–1.22)	0.177
Total ^e	1454		96	82 (5.6)			
<i>Main non-vertebral fractures (forearm/wrist, hip, humerus, leg and ribs)</i>							
0 to 6	1454	321	23	21 (1.4)	0.006 (0.002–0.018)	-	-
>6 to 12	1384	283	19	18 (1.3)	0.006 (0.002–0.016)	0.90 (0.49–1.64)	0.721
>12 to 18	1295	209	13	13 (1.0)	0.004 (0.002–0.013)	0.69 (0.35–1.36)	0.283
>18 to 24	1087	315	13	13 (1.2)	0.005 (0.002–0.018)	0.83 (0.41–1.67)	0.601
Total ^e	1454		68	61 (4.2)			

^aN = all patients with information regarding fractures within the time window

^bAs some patients experienced a fracture in more than one time interval, the total was not the sum of patients with a fracture in each interval

^cAdjusted model by gender, age, prior bisphosphonate/denosumab use, and history of vertebral or non-vertebral fracture in the 12 months before starting teriparatide.

^dCompared with 0- to 6-month interval

^eAll fractures from treatment start to end of treatment within the 24 months are included

CI, confidence interval